­­­An Integrated Autophagy-Related Gene Signature Predicts Prognosis in Human Endometrial Cancer

doi:10.21203/rs.3.rs-28245/v5

Background: Globally, endometrial cancer is the fourth most common malignant tumor in women and the number of women being diagnosed is increasing. Tumor progression is strongly related to the cell survival-promoting functions of autophagy. We explored the relationship between endometrial cancer prognoses and the expression of autophagy genes using human autophagy databases.

Methods: The Cancer Genome Atlas was used to identify autophagy related genes (ARGs) that were differentially expressed in endometrial cancer tissue compared to healthy endometrial tissue. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes were referenced to identify important biological functions and signaling pathways related to these differentially expressed ARGs. A prognostic model for endometrial cancer was constructed using univariate and multivariate Cox, and Least Absolute Shrinkage and Selection Operator regression analysis. Endometrial cancer patients were divided into high- and low-risk groups according to risk scores. Survival and receiver operating characteristic (ROC) curves were plotted for these patients to assess the accuracy of the prognostic model. Using immunohistochemistry the protein levels of the genes associated with risk were assessed.

Results: We determined 37 ARGs were differentially expressed between endometrial cancer and healthy tissues. These genes were enriched in the biological processes and signaling pathways related to autophagy. Four ARGs (CDKN2A, PTK6, ERBB2 and BIRC5) were selected to establish a prognostic model of endometrial cancer. Kaplan–Meier survival analysis suggested that high-risk groups have significantly shorter survival times than low-risk groups. The area under the ROC curve indicated that the prognostic model for survival prediction was relatively accurate. Immunohistochemistry suggested that among the four ARGs the protein levels of CDKN2A, PTK6, ERBB2, and BIRC5 were higher in endometrial cancer than healthy endometrial tissue.

Conclusions: Our prognostic model assessing four ARGs (CDKN2A, PTK6, ERBB2, and BIRC5) suggested their potential as independent predictive biomarkers and therapeutic targets for endometrial cancer.

Cancer Biology

Oncology

prognosis

autophagy

endometrial cancer

molecular biomarkers

The Cancer Genome Atlas

Autophagy is the process by which cells engulf their cytoplasmic proteins and organelles, envelop them into vesicles, and combine with lysosomes to form autolysosomes in order to renew intracellular components [1-3]. Autophagy is closely associated with the occurrence and development of various diseases, such as malignant tumors, infectious diseases, and autoimmune diseases [4-8]. However, the role of autophagy in tumors has not been fully elucidated. It is generally believed that in the initial stage of tumor formation, autophagy inhibits the growth of malignant tumors; once malignant tumors are formed, autophagy promotes the development of cancer [9, 10]. Many studies have attempted to clarify the role and complex functionalities of autophagy in malignant tumors with the intent of suppressing the development of malignancies by upregulating or inhibiting autophagy [11].

Endometrial cancer is one of the most common malignant tumors in women. It ranks fourth among the European and North American women, accounting for approximately 6% of new cancer cases and 3% of cancer deaths every year; most of the incidences occur during the perimenopausal and menopausal periods [12]. The treatment of early endometrial cancer is mainly surgical and has good prognoses. Unfortunately, recurrence and metastasis occur in some patients, for whom radiotherapy, chemotherapy, or a combination both is required; however, outcomes are poor [13-16].

The relationship between autophagy and the occurrence and development of endometrial cancer has been reported in the early studies, for example, autophagy-mediated regulation of the adaptive response to targeted therapy [17]. Previous studies have mostly focused on the role of autophagy in the development and treatment of endometrial cancer [18-20]. However, there are only a few large-scale data mining studies that have analyzed the effects of autophagy genes on the progression and prognosis of endometrial cancer. In this study, we analyzed the transcriptomic data of endometrial cancer samples downloaded from The Cancer Genome Atlas (TCGA) public database and constructed a prognostic model for endometrial cancer with four autophagy related genes (ARGs), which could accurately assess the prognostic risk of patients with endometrial cancer.

Patient information and databases

Transcript information of endometrial cancer samples was downloaded from TCGA database(https://portal.gdc.cancer.gov/), and the clinical information on these patients was downloaded from the UCSC Xena database (https://xenabrowser.net/heatp/). A total of 222 autophagy genes were obtained from the human autophagy database(http://www.autophagy.lu/).

Screening and enrichment analysis of differentially expressed genes

The Limma package in R statistical software was used to filtrate differentially expressed genes associated with autophagy (FDR Filter = 0.05,logFC filter = 1). The ClusterProfiler, org.Hs.eg.db, and ggplot2 packages in R were applied to perform enrichment analysis of all the differentially expressed ARGs using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases in order to discover the main biological characteristics of these genes [21].

Construction of prognostic models

We performed a univariate Cox regression analysis of ARGs, which were differentially expressed in endometrial cancer. Univariate Cox regression analyses were plotted using the “survival” package; a P value less than 0.05 was considered a significant difference threshold. In order to simplify the parameters of the model and avoid overfitting of the model, we carried out the Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis using the “glmnet” R package [22]. Multivariate Cox regression analysis was carried out for the genes obtained by LASSO regression, and those with a 95% confidence interval for a hazard ratio (HR) >1 or <1 were selected as parameters for the final prognostic model. The expression values of all prognostic genes were multiplied by their regression coefficients, which eventually added up to a risk score for each sample. Survival curves were plotted with the “survminer” R package, and a receiver operating characteristic (ROC) curve evaluating the accuracy of the prognostic model was constructed using the “timeROC” R package [23].

Training and validation of the prognostic model

The TCGA-Uterine Corpus Endometrial Carcinoma (UCEC) cohort was randomly split into a training set and a verification set using the “caret” R package, and the ratio was set to 1:1. We obtained a training set with 270 samples and verification set with 270 samples. The training set was used to perform multivariate Cox regression to obtain the parameters of the prognostic model, and the verification set was used to confirm the prediction accuracy of this prognostic model. The risk score of each sample in both sets was calculated and the samples were divided into a high-risk group and a low-risk group, using the median risk score as the division between high- and low-risk groups.

Immunohistochemical data of four risk ARGs

The Human Protein Atlas (HPA, https://www.proteinatlas.org/) is a database that contains a large amount of human protein data, which can help us understand the protein expression levels of specific genes in different tissues [24]. We downloaded immunohistochemical pictures of four risk ARGs in normal endometrium and endometrial cancer from this website and we calculated the ISH score of each sample (ISH score = staining intensity * staining area score). There are four levels of staining intensity: negative, 0; weak, 1; moderate, 2; and strong, 3. These correspond to five levels of staining area score: <5%, 0; 5% to 25%, 1; 5% to 50%, 2; 50% to 75%, 3; and >75%, 4.

Statistical analysis

All statistical analyses were performed using the R software (v.3.6.1. https://www.r-project.org/) and GraphPad Prism software (v.8.01; GraphPad Software, San Diego, CA, USA). Univariate Cox regression, multivariate Cox regression, and LASSO regression were used to establish the prognostic model. Kaplan-Meier plotter and ROC curve were used to evaluate the accuracy of the prognostic model. An unpaired t-test was used to compare the ISH score between the normal endometrial tissue and UCEC tissue. P < 0.05 was considered statistically significant.

Differentially expressed ARGs

We analyzed the expression of 222 ARGs in 552 endometrial cancer tissues and 35 non-tumor tissues using the Wilcoxon signed-rank test in R. We obtained 37 differentially expressed ARGs, according to the criteria of |log2FC| > 1 and FDR < 0.05. These ARGs include 19 up-regulated genes (PARP1, PRKCD, CTSB, APOL1, ATG4D, BNIP3, BAK1, P4HB, ERBB2, ERO1A, GAPDH, IKBKE, TP63, EIF4EBP1, SERPINA1, IFNG, PTK6, BIRC5, and CDKN2A) and 18 downregulated genes (ITPR1, FOS, GRID1, HSPB8, NRG3, NRG2, DLC1, BCL2, FOXO1, CCL2, PRKN, TUSC1, CDKN1B, GABARAPL1 ,ST13, RAB33B, CALCOCO2, and MYC). The volcano map (Figure 1A), heatmap (Figure 1B), and boxplot (Figure 1C) were visualized for these ARGs（Supplementary Table S1).

GO enrichment analysis of differentially expressed ARGs

GO functional enrichment analysis of these 37 differentially expressed ARGs was performed (Supplementary Table S2), and the enrichment results were visualized to understand the biological functions of these genes. The results showed these ARGs were primarily involved with the intrinsic apoptotic signaling pathway, processes utilizing the autophagic mechanism, the cellular response to oxidative stress, integral components of the mitochondrial outer membrane, autophagosome membrane, protease binding, and heat shock protein binding (Figure 2A, 2B).

KEGG enrichment analysis of differentially expressed ARGs

The results of the KEGG pathway enrichment analysis indicated that the differentially expressed ARGs were related to autophagy, apoptosis, the ErbB signaling pathway, the HIF-1 signaling pathway, cellular senescence, the AGE-RAGE signaling pathway in diabetic complications, protein processing in the endoplasmic reticulum, endometrial cancer, the FoxO signaling pathway, and the estrogen signaling pathway (Figure3, Table 1). In endometrial cancer, three differentially expressed ARGs (ERBB2, BAK1 and MYC), which are closely related to the occurrence of endometrial cancer, were increased. The estrogen signaling pathway, which is highly associated with the development of endometrial cancer, showed enrichment of four differentially expressed ARGs (ITPR1, FOS, PRKCD, and BCL2).

Survival-related ARGs and the prognostic model

We performed univariate Cox regression of 37 differentially expressed ARGs, and 9 ARGs associated with endometrial cancer prognosis were obtained, including ERBB2, CDKN2A, BAK1, GRID1, NRG3, PTK6, DLC1, P4HB, and BIRC5 (P < 0.05). Seven prognosis-related ARGs (ERBB2, CDKN2A, BAK1, GRID1, NRG3, PTK6, and BIRC5) were considered risk factors (the minimum value of the 95% CI was greater than 1), and their high expression indicates a poor prognosis. Conversely, the high expression of the remaining two genes (DLC1 and P4HB) indicates better survival. Results were visualized using a forest plot (Figure 4A).

LASSO regression analysis was then conducted to exclude genes that may be highly correlated with other genes. The complexity degree of LASSO regression is determined by the parameter lambda (λ). The larger the λ, the greater the penalty for the linear model with more variables. A model with fewer variables should be selected. We obtained 8 candidate genes (CDKN2A, ERBB2, GRID1, NRG3, PTK6, DLC1, P4HB, and BIRC5) by LASSO regression (Figure 4 B-C).

Multivariate Cox regression analysis of the training cohort indicated that CDKN2A, ERBB2, PTK6, and BIRC5 were independent prognostic factors according to the HR values (CDKN2A: 1.571; ERBB2: 2.310; PTK6: 1.355; and BIRC5: 2.375; P < 0.05)(Table 2). Therefore, these genes were used to establish a prognostic model risk score = (0.45 ∗ CDKN2A expression) + (0.84 ∗ ERBB2 expression) + (0.30 ∗ PTK6 expression) + (0.86 ∗ BIRC5 expression).

We analyzed the relationship between our prognostic model and the molecular classification of endometrial cancer, and the results showed that patients with CN high have the highest risk score according to our prognostic model, but there was no significant difference in risk between POLE, MSI-H, and CN low (Supplementary Figure S1A). We then analyzed the relationship between risk score and clinicopathological parameters in UCEC, and the results indicated that high-risk score also correlated significantly with older age, higher FIGO stage, higher neoplasm histologic grade, histological type, and higher BMI in UCEC (Supplemental Table S4). Furthermore, we have performed the COX analysis again and included risk score, age, histological type, and FIGO stage, and the results showed that, like traditional endometrial cancer prognostic markers, the prognostic score obtained by our prognostic model was also an independent prognostic factor for endometrial cancer, with an HR of 2.627 and a p-value less than 0.01(Supplemental Table S5, Supplemental Figure S1B).

We used the median risk value to divide the training set and the verification set into a high-risk group and a low-risk group. Kaplan–Meier plotter results showed that survival rates for high-risk patients in the training set for 1, 3, and 5 years were 76.0%, 30.1%, and 13.2%, respectively and survival rates for low-risk patients in the training set for 1, 3, and 5 years were 91.0%, 45.6%, and 27.9%, respectively (Figure 5A). To evaluate the predictive accuracy of the prognostic model, we also plotted a ROC curve, where the area under the curve (AUC) was 0.755 for one-year survival, 0.790 for three-year survival, and 0.800 for five-year survival (Figure 5B).

Similarly, we conducted a survival analysis in the verification set, and the results showed that survival rates for high-risk patients in the verification set for 1, 3, and 5 years were 82.2%, 27.4%, and 13.3%, respectively, while survival rates for low-risk patients in the verification set for 1, 3, and 5 years were 88.1%, 45.2%, and 25.2%, respectively (Figure 5C). To evaluate the predictive accuracy of the prognostic model, we also plotted a ROC curve, where the AUC was 0.699 for one-year survival, 0.836 for three-year survival, and 0.820 for five-year survival (Figure 5D). Besides, AUC curves of other risk factors were also plotted to compare the prognostic value of different criteria, and the results showed that our prognostic model was indeed better than traditional prognostic indicators in predicting the survival of patients with endometrial cancer, including clinical grade, age, etc.(Supplemental Figure S2).

In addition to using survival curves to validate our prognostic model, we plotted risk curves for patients with endometrial cancer in the training set and the verification set. In both sets, as the patient's risk value increased, patient mortality increased significantly. A heatmap showed expression of risk genes was up-regulated in the high-risk groups. The results from the training and verification sets were internally consistent (Figure 6 A-F).

Validation of risk genes at the protein level

Immunohistochemistry revealed ISH scores for four risk ARGs (CDKN2A, ERBB2, PTK6, and BRIC5) were significantly higher in endometrial cancer tissue than in healthy endometrial tissue, which suggested that these genes are highly expressed in endometrial cancer tissues. We also found that CDKN2A was mainly located in the cytoplasm, membrane, and nucleus, while ERBB2, BRIC5, and PTK6 were mainly located in the cytoplasm and membrane. All immunohistochemical results were derived from the HPA database (Figure 7), the corresponding data are referenced on Table S3.

Endometrial cancer is the fourth most common malignant tumor in women worldwide, and its incidence is still increasing in recent years [25]. Although most patients with endometrial cancer are postmenopausal women, the incidence in young women has dramatically increased as a result of early-onset obesity and hyperinsulinemia. It is speculated that one-third of women will suffer from endometrial cancer during their lifetime [26, 27].

The role of autophagy in tumor progression is not yet clear. It has been reported that in the early stages of tumorigenesis, autophagy can inhibit tumor growth by inhibiting tumor necrosis, and as the tumor continues to develop, autophagy protects tumors by promoting tumor vascularization and distant metastasis [28]. In the field of endometrial cancer research, it has been reported that isoliquiritigenin (ISL) can induce autophagy in endometrial cancer cells, thereby exerting a cancer-suppressing effect [29]. High levels of estrogen affect glutathione metabolism by increasing the level of glutaminase, thereby inhibiting autophagy in endometrial cancer and promoting its growth [30]. Kanda R, et al. showed that glucagon-like peptide-1 receptor (GLP-1R) promotes autophagy in endometrial cancer, thereby inhibiting its growth and suggesting GLP-1R agonists as a potential therapeutic strategy [31].

Previous studies have mostly focused on the mechanism of autophagy in regulating tumorigenesis and the development of endometrial cancer. In this study, we sorted and analyzed the transcript information of endometrial cancer samples retrieved from TCGA database and screened out 37 differentially expressed ARGs. GO enrichment analysis found that most of these genes are part of the intrinsic apoptotic signaling pathway, processes utilizing the autophagic mechanism, and cellular responses to oxidative stress, which are important functions of autophagy. The autophagy process can remove abnormal proteins and damaged organelles produced by cells under oxidative stress, thus becoming an important guarantee for the health and survival of cells. Previous studies reported that autophagy can promote mammalian cell survival by inhibiting oxidative stress and TP53 function [32, 33]. KEGG analysis found that most of these genes are mainly involved in autophagy, apoptosis, the HIF-1, and ERBB signaling pathways. Activation of autophagy promotes tumor metastasis by inducing HIF-1α, and it was verified that HIF-1 modulates the induction of autophagic proteins through regulating the association between Beclin1 and Bcl-2 [34, 35]. The ERBB receptors transduce signals through Akt, MAPK, and many other pathways to regulate cell proliferation, migration, differentiation, and apoptosis. It was reported that endogenous HER2 interacts with Beclin1 in breast cancer cells to inhibit autophagy, and that Beclin1 mutation reduces Beclin1/HER2 binding to promote autophagy in HER2-positive breast cancer cells [36].

We constructed a prognostic model of endometrial cancer containing four risk ARGs (CDKN2A, PTK6, ERBB2, and BIRC5) using multivariate and univariate Cox, and LASSO regression analyses. By performing survival analysis on the training set and test set and drawing ROC curves, we proved that our model can predict the prognosis for endometrial cancer patients based on risk factors and that the accuracy of the model was relatively high.

CDKN2A contains two introns and three exons and generates several transcript variants, which differ in their first exons, including the p16^INK4a and P14^ARFproteins, which are negative regulators of the cell cycle [37-39]. The expression of the P14^ARF gene in endometrial cancer is significantly higher than in normal endometrium, but the relationship between P14^ARF and endometrial cancer prognoses was not investigated [40]. A previous study reported that CDK inhibitors induce cytotoxicity by enhancing apoptosis in CDKN2A-defective SqCLC cells, resulting in increased autophagy during this process [41]. Furthermore, García-Prat L et al. reported that monoubiquitination of lysine 119 (H2Aub) at the INK4a locus drives p16^INK4a induction in geriatric satellite cells, which promotes autophagy [42]. Capparelli C et al. found that p16^INK4a-overexpressing fibroblast cell lines significantly promoted tumor growth and the expression of p16^INK4a was associated with the induction of markers of senescence, autophagy, and mitophagy in epithelial cancer cells[43]. Moreover, Witkiewicz AK et al. reported that p16^INK4a was elevated in ductal carcinoma in situ and stoma of breast cancer, and that elevated p16^INK4a expression was closely related to disease recurrence [44]. Furthermore, CDKN2A was thought to inhibit tumor growth [41]; however, the mechanisms that promote tumor progression remain unclear. In the present study, we identified elevated CDKN2A expression as an independent risk factor for endometrial cancer, with higher levels of CDKN2A expression corresponding with worse prognosis for patients with endometrial cancer. A possible explanation for this is that CDKN2A overexpression in the stroma might affect the tumor microenvironment through the secretion of cytokines and proteases and promote the growth of endometrial cancer [45, 46].

PTK6 encodes a cytoplasmic non-receptor protein kinase. PTK6 antagonists can inhibit metastasis in triple-negative breast cancer and PTK6 activation can promote epithelial-to-mesenchymal transition in prostate cancer [47]. PTEN suppresses oncogenic signaling for prostate cancer through dephosphorylation of PTK6 tyrosine 342(PY342), and PTK6 facilitates cell migration and proliferation by phosphorylating Esp8 [48]. PTK6 is also involved in autophagy related signaling pathways, and there are reports that PTK6 can promote ERBB2-induced mammary gland tumorigenesis. Additionally, STAT3, FAK, and BCAR1 are relevant PTK6 substrates in breast cancer , and PTK6 protects breast cancer cells from autophagic cell death induced by loss of anchorage, suggesting that PTK6 can inhibit autophagic processes [49]. In the present study, we found that elevated PTK6 expression was associated with worse prognoses, suggesting that PTK6 might promote endometrial cancer progression by inhibiting autophagy.

ERBB2, also known as HER2 in humans, encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. The overexpression of the HER2 protein was seen in approximately 25%–30% of breast and ovarian cancers [50]. In high-grade endometrial cancer, the HER2 gene is amplified by17%–30% and up to 80% of tumors exhibit HER2 protein overexpression [51, 52]. HER2 is an important signaling pathway in tumor growth and involved in regulating autophagy, blockage of HER2/Beclin1 binding increases autophagy, with a previous study finding that HER2 interacts with Beclin1 in breast cancer cells and inhibits autophagy [36]. Moreover, HER2-targeted therapy induces autophagy in esophageal cancer, and autophagy inhibitors significantly reduce resistance to the HER2 inhibitor lapatinib [53]. Furthermore, a previous study reported that protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib, suggesting that HER2 regulates protective autophagy [54, 55]. In the present study, we identified HER2 as an independent risk factor for endometrial cancer through multivariate Cox regression analysis (HER2 HR: 2.3), suggesting that HER2 might promote the progression of endometrial cancer by inhibiting autophagy.

BIRC5 is a member of the inhibitor of apoptosis gene family, which encode negative regulatory proteins that prevent apoptotic cell death. A previous study found that miR-203 inhibits ovarian tumor metastasis by targeting BIRC5/survivin and that BIRC5/survivin can also serve as a target for glycolysis inhibition in high-stage neuroblastoma [56]. Yu X, et al. reported BIRC5 overexpression in non-small cell lung cancer (NSCLC), and that miR-195 targets BIRC5 to induce apoptosis and senescence in NSCLC cells [57]. Lin et al. demonstrated that BIRC5 directly regulates autophagy by modulating the protein stability of ATG7 and physically binding to the ATG12–ATG5 conjugate. Additionally, BIRC5 negatively modulates the protein stability of ATG7 and physically binds to the ATG12–ATG5 conjugate, thereby preventing formation of the ATG12–ATG5–ATG16L1 protein complex in human cancer and suggesting that BIRC5 can directly regulate autophagy in cancer cells [58]. In the present study, we found that BIRC5 was significantly overexpressed in endometrial cancer and an independent prognostic factor, suggesting that BIRC5 might promote endometrial cancer by inhibiting autophagy in cancer cells.

A limitation of our study is that it is mainly based on data from TCGA and human autophagy databases. ARGs mechanism in promoting the occurrence and progression of endometrial cancer has not yet been elucidated. Further research and experimental studies are needed to verify whether the progress of endometrial cancer can be suppressed by downregulating these ARGs.

In summary, by collecting and analyzing the transcript information of endometrial cancer samples from TCGA database, we identified four prognosis-associated autophagy genes (CDKN2A, PTK6, ERBB2, and BIRC5). These genes have potential as new biomarkers or therapeutic targets; however, their effects and mechanism of action need further experimental verification prior to clinical implementation.

UCEC: Uterine Corpus Endometrial Carcinoma; TCGA: The Cancer Genome Atlas; ARGs: autophagy related genes; CI: Confidence interval; OS: Overall survival; ROC: Receiver operating characteristic; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; LASSO: Least Absolute Shrinkage and Selection Operator; HR: hazard ratio; HPA: Human Protein Atlas; ISH: Immunohistochemistry; AUC :area under the curve.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

All analyzed data are included in this published article and its supplementary information file. The original data are available from the corresponding author on

reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported in part by the Fundamental Research Funds for the Central Universities (No. 2020kfyXGYJ085). The funding bodies did not have any influence on the design of the study, collection,analysis, interpretation of data or writing of manuscript.

Author contributions

JZ and HW conceived and supervised the study; ZW and RZ obtained the data and performed preliminary analyses; JZ and HW wrote and revised the manuscript; LA, XZ, and YZ proofread the manuscript; and all authors read and approved the final version of the manuscript.

Acknowledgements

We appreciate the Cancer Genome Atlas and The Human Protein Atlas for the open data.

Author information

Affiliations

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Jun Zhang, Ziwei Wang, Rong Zhao, Lanfen An, Xing Zhou & Hongbo Wang

Department of Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Yingchao Zhao

Corresponding author

Correspondence to Hongbo Wang

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Parzych KR, Klionsky DJ: An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal 2014, 20(3):460-473.
Mizushima N, Komatsu M: Autophagy: renovation of cells and tissues. Cell 2011, 147(4):728-741.
Ravanan P, Srikumar IF, Talwar P: Autophagy: The spotlight for cellular stress responses. Life Sci 2017, 188:53-67.
Mowers EE, Sharifi MN, Macleod KF: Functions of autophagy in the tumor microenvironment and cancer metastasis. Febs j 2018, 285(10):1751-1766.
Rockel JS, Kapoor M: Autophagy: controlling cell fate in rheumatic diseases. Nat Rev Rheumatol 2016, 12(9):517-531.
Nixon RA, Yang DS: Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb Perspect Biol 2012, 4(10).
Hirata E, Sahai E: Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harb Perspect Med 2017, 7(7).
Cui J, Jin S, Wang RF: The BECN1-USP19 axis plays a role in the crosstalk between autophagy and antiviral immune responses. Autophagy 2016, 12(7):1210-1211.
Jiang GM, Tan Y, Wang H, Peng L, Chen HT, Meng XJ, Li LL, Liu Y, Li WF, Shan H: The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Mol Cancer 2019, 18(1):17.
Poillet-Perez L, White E: Role of tumor and host autophagy in cancer metabolism. Genes Dev 2019, 33(11-12):610-619.
Levy JMM, Towers CG, Thorburn A: Targeting autophagy in cancer. Nat Rev Cancer 2017, 17(9):528-542.
Murali R, Soslow RA, Weigelt B: Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014, 15(7):e268-278.
Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T et al: Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol 2014, 134(2):385-392.
Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR, Ghaem-Maghami S: Endometrial cancer. Bmj 2011, 343:d3954.
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I: Endometrial cancer. Lancet 2005, 366(9484):491-505.
Hunn J, Dodson MK, Webb J, Soisson AP: Endometrial cancer--current state of the art therapies and unmet clinical needs: the role of surgery and preoperative radiographic assessment. Adv Drug Deliv Rev 2009, 61(10):890-895.
Eritja N, Chen BJ, Rodríguez-Barrueco R, Santacana M, Gatius S, Vidal A, Martí MD, Ponce J, Bergadà L, Yeramian A et al: Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 2017, 13(3):608-624.
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC, Zhang DM, Chen ZS: Autophagy and multidrug resistance in cancer. Chin J Cancer 2017, 36(1):52.
Chen P, Cescon M, Bonaldo P: Autophagy-mediated regulation of macrophages and its applications for cancer. Autophagy 2014, 10(2):192-200.
Farrow JM, Yang JC, Evans CP: Autophagy as a modulator and target in prostate cancer. Nat Rev Urol 2014, 11(9):508-516.
Yu G, Wang LG, Han Y, He QY: clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 2012, 16(5):284-287.
Friedman J, Hastie T, Tibshirani R: Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw 2010, 33(1):1-22.
Blanche P, Dartigues JF, Jacqmin-Gadda H: Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 2013, 32(30):5381-5397.
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A et al: Proteomics. Tissue-based map of the human proteome. Science 2015, 347(6220):1260419.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015, 65(2):87-108.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015, 65(1):5-29.
Urick ME, Bell DW: Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer 2019, 19(9):510-521.
Kenific CM, Thorburn A, Debnath J: Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol 2010, 22(2):241-245.
Wu CH, Chen HY, Wang CW, Shieh TM, Huang TC, Lin LC, Wang KL, Hsia SM: Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice. Oncotarget 2016, 7(45):73432-73447.
Zhou WJ, Zhang J, Yang HL, Wu K, Xie F, Wu JN, Wang Y, Yao L, Zhuang Y, Xiang JD et al: Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism. Cell Commun Signal 2019, 17(1):99.
Kanda R, Hiraike H, Wada-Hiraike O, Ichinose T, Nagasaka K, Sasajima Y, Ryo E, Fujii T, Osuga Y, Ayabe T: Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer 2018, 18(1):657.
Peker N, Gozuacik D: Autophagy as a Cellular Stress Response Mechanism in the Nervous System. J Mol Biol 2020.
Yang Y, Karsli-Uzunbas G, Poillet-Perez L, Sawant A, Hu ZS, Zhao Y, Moore D, Hu W, White E: Autophagy promotes mammalian survival by suppressing oxidative stress and p53. Genes Dev 2020.
Indelicato M, Pucci B, Schito L, Reali V, Aventaggiato M, Mazzarino MC, Stivala F, Fini M, Russo MA, Tafani M: Role of hypoxia and autophagy in MDA-MB-231 invasiveness. J Cell Physiol 2010, 223(2):359-368.
Bohensky J, Shapiro IM, Leshinsky S, Terkhorn SP, Adams CS, Srinivas V: HIF-1 regulation of chondrocyte apoptosis: induction of the autophagic pathway. Autophagy 2007, 3(3):207-214.
Vega-Rubín-de-Celis S, Zou Z, Fernández Á F, Ci B, Kim M, Xiao G, Xie Y, Levine B: Increased autophagy blocks HER2-mediated breast tumorigenesis. Proc Natl Acad Sci U S A 2018, 115(16):4176-4181.
Zhao R, Choi BY, Lee MH, Bode AM, Dong Z: Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer. EBioMedicine 2016, 8:30-39.
Witcher M, Emerson BM: Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 2009, 34(3):271-284.
Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366(6456):704-707.
Watanabe J, Nishizaki R, Jobo T, Kamata Y, Hata H, Nishimura Y, Fujisawa T, Okayasu I, Kuramoto H: Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus. Int J Gynecol Pathol 2004, 23(3):234-240.
Jeong EH, Lee TG, Ko YJ, Kim SY, Kim HR, Kim H, Kim CH: Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells. Cell Oncol (Dordr) 2018, 41(6):663-675.
García-Prat L, Martínez-Vicente M, Perdiguero E, Ortet L, Rodríguez-Ubreva J, Rebollo E, Ruiz-Bonilla V, Gutarra S, Ballestar E, Serrano AL et al: Autophagy maintains stemness by preventing senescence. Nature 2016, 529(7584):37-42.
Capparelli C, Chiavarina B, Whitaker-Menezes D, Pestell TG, Pestell RG, Hulit J, Andò S, Howell A, Martinez-Outschoorn UE, Sotgia F et al: CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 2012, 11(19):3599-3610.
Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES: Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol 2011, 179(3):1171-1178.
Davalos AR, Coppe JP, Campisi J, Desprez PY: Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010, 29(2):273-283.
Coppé JP, Desprez PY, Krtolica A, Campisi J: The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010, 5:99-118.
Zheng Y, Wang Z, Bie W, Brauer PM, Perez White BE, Li J, Nogueira V, Raychaudhuri P, Hay N, Tonetti DA et al: PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Res 2013, 73(17):5426-5437.
Shin WS, Shim HJ, Lee YH, Pyo M, Park JS, Ahn SY, Lee ST: PTK6 Localized at the Plasma Membrane Promotes Cell Proliferation and MigratiOn Through Phosphorylation of Eps8. J Cell Biochem 2017, 118(9):2887-2895.
Peng M, Ball-Kell SM, Tyner AL: Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse. Cell Death Dis 2015, 6(8):e1848.
Moasser MM: The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26(45):6469-6487.
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004, 22(15):3126-3132.
English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD: HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol 2013, 131(3):753-758.
Janser FA, Adams O, Bütler V, Schläfli AM, Dislich B, Seiler CA, Kröll D, Langer R, Tschan MP: Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells. Int J Mol Sci 2018, 19(10).
Lindqvist LM, Vaux DL: BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy. Autophagy 2014, 10(8):1474-1475.
Lindqvist LM, Heinlein M, Huang DC, Vaux DL: Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak. Proc Natl Acad Sci U S A 2014, 111(23):8512-8517.
Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ: BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma. Oncogene 2016, 35(16):2052-2061.
Yu X, Zhang Y, Cavazos D, Ma X, Zhao Z, Du L, Pertsemlidis A: miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis 2018, 9(2):193.
Lin TY, Chan HH, Chen SH, Sarvagalla S, Chen PS, Coumar MS, Cheng SM, Chang YC, Lin CH, Leung E et al: BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells. Autophagy 2019:1-18.

Table 1. KEGG enrichment results for differentially expressed ARGs.

ID	Description	P	geneID
hsa04140	Autophagy - animal	7.80E−06	ITPR1/CTSB/PRKCD/ ATG4D/GABARAPL1/ BNIP3/RAB33B/ BCL2
hsa04210	Apoptosis	4.99E−05	PARP1/ITPR1/FOS/CTSB/ BAK1 /BCL2/BIRC5
hsa04012	ErbB signaling pathway	4.99E−05	CDKN1B/NRG2/ERBB2/ MYC/EIF4EBP1/NRG3
hsa04066	HIF-1 signaling pathway	1.62E−04	CDKN1B/ERBB2/IFNG/ BCL2/GAPDH/EIF4EBP1
hsa04621	NOD-like receptor signaling pathway	1.94E−04	ITPR1/CTSB/PRKCD/ GABARAPL1/CCL2/ BCL2/IKBKE
hsa01522	Endocrine resistance	8.02E−04	CDKN1B/FOS/ERBB2/ CDKN2A/BCL2
hsa04933	AGE-RAGE signaling pathway in diabetic complications	8.02E−04	CDKN1B/PRKCD/FOXO1/ CCL2/BCL2
hsa04137	Mitophagy - animal	1.84E−03	CALCOCO2/PRKN/ GABARAPL1/BNIP3
hsa01521	EGFR tyrosine kinase inhibitor resistance	2.62E−03	NRG2/ERBB2/BCL2/ EIF4EBP1
hsa04215	Apoptosis - multiple species	2.62E−03	BAK1/BCL2/BIRC5
hsa04218	Cellular senescence	3.49E−03	ITPR1/FOXO1/CDKN2A/ MYC/EIF4EBP1
hsa04141	Protein processing in endoplasmic reticulum	3.57E−03	ERO1A/PRKN/BAK1/ BCL2/P4HB
hsa05213	Endometrial cancer	9.22E−03	ERBB2/BAK1/MYC
hsa04068	FoxO signaling pathway	1.00E−02	CDKN1B/FOXO1/ GABARAPL1/BNIP3
hsa04915	Estrogen signaling pathway	1.17E−02	ITPR1/FOS/PRKCD/BCL2

Table 2. The results of univariate and multivariate Cox regression analysis.

Gene	Univariate		Multivariate
Gene	HR(95%CI)	P	HR(95%CI)	P
ERBB2	2.746(1.616-4.665)	0.001	2.310(1.084-4.923)	0.030
CDKN2A	1.27(1.130-1.427)	0.000	1.571(1.290-1.914)	0.000
BAK1	1.496(1.109-2.019)	0.008
GRID1	1.296(1.022-1.644)	0.037
NRG3	1.328(1.127-1.564)	0.000
PTK6	1.27(1.073-1.504)	0.006	1.355(1.062-1.730)	0.015
DLC1	0.550(1.367-0.822)	0.004
P4HB	0.626(0.426-0.921)	0.017
BIRC5	2.132(1.046-4.346)	0.033	2.375(1.147-4.917)	0.020

Regression coefficients, P values, HRs, and 95% confidence intervals of the prognosis-related autophagy genes are shown.

SupplementaryFigureS1.tif
Supplementary Figure S1.(A) Distribution of risk score among four different subtypes of endometrial cancer, POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high.(B) Forest plots visualizing the HRs of clinicopathological criteria identified by multivariate Cox analysis.
SupplementaryFigureS2.tif
Supplementary Figure S2.(A-D) Time-dependent ROC curves of different clinicopathological criteria for predicting one-year, three-year, and five-year survival of endometrial cancer.
TableS1.xlsx
Additional file1:Table S1. List of differentially expressed ARGs between EC tissue and normal endometrial tissue in the TCGA dataset.
TableS2.xlsx
Additional file2:Table S2.Gene ontology enrichment analysis of the differentially expressed ARGs in the TCGA dataset.
TableS3.xlsx
Additional file3: Table S3. Immunohistochemical data of four risk ARGs.
TableS4.xlsx
Additional file4: Table S4. Clinical and pathological characteristics of high and low risk patients.
TableS5.xlsx
Additional file5: Table S5. COX analysis of age, histological type, FIGO stage and risk score.

­­­An Integrated Autophagy-Related Gene Signature Predicts Prognosis in Human Endometrial Cancer

Status:

Journal Publication

Version 5

Abstract

Figures

Background

Methods